Roche
gene testing key to $1.7 billion deal for Blueprint
cancer drug
Send a link to a friend
[July 14, 2020]
By John Miller
ZURICH (Reuters) - Roche <ROG.S> has struck
a $1.7 billion cancer drug pact with Blueprint Medicines <BPMC.O>, it
said on Tuesday, as advances in genetic testing for rare mutations drive
lucrative deals for expensive treatments.
|
The Swiss drugmaker will pay $675 million in cash and make a $100
million equity investment in Blueprint for rights to pralsetinib,
which could gain U.S. approval against so-called RET-altered
non-small cell lung cancer in November.
U.S. company Blueprint, which has been working with Roche since
2016, could also receive up to $927 million in milestone payments,
plus royalties on sales outside the United States, Roche said in a
statement.
Mutations to the RET gene can drive tumour growth, but given that
such genetic changes occur in only a fraction of patients with lung
or thyroid cancer, genetic testing is key to prescribing the most
beneficial drugs.
![](http://archives.lincolndailynews.com/2020/Jul/14/images/ads/current/contractorsreadymix_sda_HG_2020.png)
Roche's diagnostics division is key to a deal that will enable the
company to expand on a portfolio of medicines such as Alecensa and
Rozlytrek, which require testing to determine which patients will
benefit.
"We will leverage our global reach and expertise in oncology, as
well as our capabilities in diagnostics," said James Sabry, Roche's
head of partnerships.
Beyond lung cancer, Blueprint has also submitted pralsetinib to the
U.S. Food and Drug Administration (FDA) for treating advanced RET
mutant and RET fusion-positive thyroid cancers.
Roche and Blueprint are not alone in combining sophisticated
diagnostics with niche drugs.
[to top of second column] |
![](http://archives.lincolndailynews.com/2020/Jul/14/images/ads/current/heartland_discover_lda_April_2020.png)
Eli Lilly and Co <LLY.N> and German drugmaker Bayer's <BAYGn.DE> Vitrakvi also
targets tumours with a rare mutations identified by testing. Novartis <NOVN.S>
and Incyte <INCY.O>, meanwhile, won approval this year for lung cancer drug
Tabrecta, which also requires genetic testing.
Both Tabrecta and Vitrakvi rely on a diagnostic test from Roche's Foundation
Medicine diagnostics unit.
Though such gene mutations affect relatively few patients, the companies aim to
turn their medicines into blockbusters by commanding prices running into the
tens of thousands of dollars per month.
Tabrecta costs $18,000 a month, Roche's Rozlytrek is priced similarly and
Vitrakvi lists at $32,800 a month.
(Reporting by John Miller; Editing by Brenna Hughes Neghaiwi and David Goodman)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
![](http://archives.lincolndailynews.com/2016/Aug/26/images/ads/current/ldn_sda_062409.png) |